Skip to content

Prevalence and Determinants of Obesity in PKU Patients

Phenylketonuria Associated With Obesity: a Cross-sectional Pilot Study on Prevalence and Possible Contributive Factors

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07703020
Enrollment
100
Registered
2026-07-14
Start date
2026-03-01
Completion date
2029-02-01
Last updated
2026-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Phenylketonuria (PKU)

Keywords

phenylalanine, obesity, diet

Brief summary

This observational cross-sectional multicenter study aims to assess the prevalence of overweight and obesity in adult patients with phenylketonuria (PKU) and to identify associated risk factors. Adult PKU patients followed in metabolic centers in Switzerland and Austria will be evaluated using clinical data, laboratory parameters, and standardized questionnaires addressing diet, physical activity, and psychological factors. The study seeks to better understand contributors to weight gain in this population to inform preventive strategies.

Interventions

None listed

Sponsors

Christel Tran
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Confirmed diagnosis of phenylketonuria (PKU) by biochemical and/or molecular testing. * Age ≥ 18 years. * Ability to provide written informed consent.

Exclusion criteria

* Pregnant or lactating women. * Inability to follow the study procedures (e.g., due to language barriers). * Eligible participants who refuse to be informed of any important health concern discovered during the study. * Investigators, their family members, employees, or anyone with a personal link to the investigator other than a doctor-patient relationship.

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of overweight and obesity in adult PKU patientsAt enrollmentDefined according to WHO BMI categories (overweight: 25.0-29.9 kg/m²; obesity class I-III: ≥30.0 kg/m²)

Secondary

MeasureTime frameDescription
Dietary adherence in adult PKU patients (self-reported adherence questionnaire)At enrollmentMeasured as the percentage (%) of participants classified as adherent, partially adherent, or non-adherent to dietary treatment.
Dietary intake in adult PKU patients (24-hour dietary recall)At enrollmentMeasured as daily intake (continuous variables) including total energy (kcal/day), phenylalanine (mg/day), protein (g/day), carbohydrates (g/day), lipids (g/day), and amino acid mixtures (g/day).
Disordered eating behaviors (Eating Disorder Examination Questionnaire, EDE-Q)At enrollmentMeasured as global EDE-Q score (continuous scale).
Depressive symptoms (Patient Health Questionnaire-9, PHQ-9)At enrollmentMeasured as total PHQ-9 score (0-27). Higher scores mean worse outcomes
Physical activity level (Global Physical Activity Questionnaire, GPAQ)At enrollmentMeasured as total physical activity (Days-hours-minutes/week). Higher scores mean better outcome
Plasma phenylalanine levels (metabolic control)Retrospective (12 months prior to inclusion)Measured as mean phenylalanine concentration (µmol/L) over the previous 12 months
Plasma tyrosine levelsRetrospective (12 months prior to inclusion)Measured as mean tyrosine concentration (µmol/L) over the previous 12 months
Serum total cholesterol levelsRetrospective (12 months prior to inclusion)Measured as concentration (mmol/L) from available laboratory data.
Serum triglyceride levelsRetrospective (12 months prior to inclusion)Measured as concentration (mmol/L) from available laboratory data.
Blood glucose levelsRetrospective (12 months prior to inclusion)Measured as concentration (mmol/L) from available laboratory data.
Thyroid-stimulating hormone (TSH) levelsRetrospective (12 months prior to inclusion)Measured as concentration (mIU/L) from available laboratory data.
Vitamin B12 levelsRetrospective (12 months prior to inclusion)Measured as concentration (pmol/L) from available laboratory data.
Folate (vitamin B9) levelsRetrospective (12 months prior to inclusion)Measured as concentration (nmol/L) from available laboratory data.
Sapropterin treatment exposureAt enrollmentMeasured as percentage (%) of participants receiving sapropterin (yes/no).

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 15, 2026